phospho-Bcl 10 (Ser218)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3011R
英文名称phospho-Bcl 10 (Ser218)
中文名称磷酸化叠肠濒-10抗体
别 名B cell lymphoma/leukemia10; AI132454; B cell CLL/lymphoma 10; B-cell leukemia/lymphoma 10; Bcl 10; Bcl-10; Bcl10; c E10; c-E10; C81403; CARD containing apoptotic signaling protein; CARD containing molecule enhancing NF kappa B; CARD containing molecule enhancing NF kB; CARD containing molecule enhancing NFkB; CARD containing proapoptotic protein; CARD like apoptotic protein; CARMEN; cE10 antibody; CED 3/ICH 1 prodomain homologous E10 like regulator; CED3/ICH1 prodomain homologous E10 like regulator; Cellular E10; Cellular homolog of vCARMEN; CIPER; CLAP; hCLAP; Mammalian CARD containing adapter molecule E10; mE 10; mE10; R-RCD1; BCL10_RAT .
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 信号转导 细胞凋亡
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-Bcl 10 (Ser218)抗体交叉反应 Human, Mouse, Rat,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量26kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from rat Bcl10 around the phosphorylation site of Ser218:GN(p-S)SE
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-Bcl 10 (Ser218)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
Bcl10/CIPER/CLAP/mE10 is expressed in many human and murine tissues. It contains a CARD (caspase recruiting domain) domain and is involved in activation of caspase9 to induce apoptosis. It is a cellular homolog of equine herpesvirus 2 E-10. It is known to induce activation of JNK, p38 and NF kappaB. Mutations in Bcl10 are observed in many B and T cell lymphomas implicating its role in pathogenesis of human cancer.
Function:
Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1.
Subunit:
Found in a membrane raft complex, at least composed of BCL10, CARD11, DPP4 and IKBKB. Self-associates by CARD-CARD interaction and forms a tight complex with MALT1. Interacts with other CARD-proteins such as CARD9, CARD10, CARD11 and CARD14. Binds caspase-9 with its C-terminal domain. Interacts with TRAF2 and BIRC2/c-IAP2. Interacts with PELI2 and SOCS3; these interactions may be mutually exclusive (By similarity).
Subcellular Location:
Cytoplasm, perinuclear region. Membrane raft. Note=Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts.
Tissue Specificity:
Ubiquitous.
Post-translational modifications:
Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2. Phosphorylated by IKBKB/IKKB.
DISEASE:
Note=A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
Note=Defects in BCL10 are involved in various types of cancer.
Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. Note=The gene represented in this entry may be involved in disease pathogenesis.
Similarity:
Contains 1 CARD domain.
phospho-Bcl 10 (Ser218)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
phospho-Bcl 10 (Ser218)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 AKT3 蛋白激酶B3
合格 合格 Cdc7 细胞分裂周期蛋白7抗体
合格 phospho-LSP1 (Ser252) 磷酸化白细胞F肌动蛋白结合蛋白抗体
合格 FHL2 相互作用蛋白FHL2抗体
合格 MYLPF 快速骨骼肌肌球蛋白轻链2抗体
合格 phospho-Amyloid Precursor Protein (Ser730) 磷酸化APP淀粉样肽前体蛋白抗体
合格 合格 phospho-ATF2 (Ser322) 磷酸化活化复制因子2抗体
合格 合格 phospho-ATF2 (Ser62 / Ser44) 磷酸化活化复制因子2抗体
合格 phospho-ATF2 (Ser94) 磷酸化活化复制因子2抗体
合格 phospho-ATF2 (Thr51) 磷酸化活化复制因子2抗体
合格 phospho-APC1 (Ser377) 磷酸化细胞周期末期促进复合蛋白APC1抗体
合格 phospho-DDIT3 (Ser30) 磷酸化GADD153抗体
合格 phospho-AXL (Tyr698+Tyr702+Tyr703) 磷酸化粘附相关激酶抗体
合格 合格 合格 phospho-AKT1 + AKT2 + AKT3 (Thr308+Thr309+Thr305) 磷酸化蛋白激酶B抗体
合格 phospho-AQP2 (Ser264) 磷酸化水通道蛋白2抗体
合格 phospho-Androgen Receptor (Ser213) 磷酸化雄**受体抗体
合格 合格 合格 phospho-AKT1+AKT2+AKT3 (Tyr315+316+312) 磷酸化蛋白激酶AKT1,2,3抗体
合格 合格 合格 phospho-AKT1(Thr34) 磷酸化蛋白激酶B抗体
合格 phospho-ATG4D (Ser467) 磷酸化自噬相关蛋白4D抗体
合格 phospho-ATG3 (Tyr18) 磷酸化自噬相关蛋白3抗体
合格 phospho-AKT3 (Ser472) 磷酸化蛋白激酶AKT3抗体
合格 Phospho-Bad (Ser118) 磷酸化相关死亡促进因子抗体
合格 合格 合格 Phospho-Bcl-2 (Thr129) 磷酸化Bcl-2抗体
合格 Cardiodilatin-related peptide 心舒血管素相关肽抗体
合格 合格 合格 phospho-CDKN1B (Thr157) 磷酸化P27抗体/周期素依赖激酶抑制剂抗体
合格 phospho-CDKN1B (Thr187) 磷酸化P27抗体/周期素依赖激酶抑制剂抗体
合格 phospho-Bid (Ser61) 磷酸化BH3结构域凋亡诱导蛋白抗体
合格 phospho-Bcl-xL (Thr115) 磷酸化Bcl-xL蛋白抗体
合格 合格 phospho-Smad3 (Ser204) 磷酸化细胞信号转导分子SMAD3抗体
合格 phospho-CDKN1A/p21 (Thr145) 磷酸化p21蛋白抗体
合格 phospho-CDKN1A/p21 (Thr57) 磷酸化p21蛋白抗体
合格 phospho-CDKN1A/p21 (Ser146) 磷酸化p21蛋白抗体
合格 Phospho-Caspase-9 (Ser196) 磷酸化半胱氨酸蛋白酶9抗体